Cynvenio inks deal with Milenia Labs to distribute blood test
Westlake Village cancer treatment company Cynvenio Biosystems announced an exclusive agreement with diagnostic test company Milenia Labs to distribute a blood test for breast cancer at its 12 diagnostic centers in Mexico.
Financial details of the deal were not disclosed.
The test provides real-time information about cancer cell activity for patients who have completed treatment or are being treated for advanced breast cancer and indicates whether the cells might be resistant to therapy.
“Milenia Labs has a successful track record of innovation in Mexico and an enviable network of partner labs throughout the country,” Humberto Huerta, Cynvenio chief commercial officer for clinical diagnostics, said in a news release. “This agreement is the cornerstone of our plan to broaden access to ClearID Breast testing services outside the United States.”
Liquid biopsy products are non-invasive and offer a better understanding of cancer genes, Dr. Salvador Cardona, director general for Milenia Labs, said. The Mexican company will also distribute other Cynvenio products, such as its PD-L1 gene expression reflex assay, as they come on the market, the release stated.
• Contact Marissa Nall at [email protected].
